HPV nonavalent vaccine (Gardasil-9)
Phase 3Vaccine
HPV nonavalent vaccine (Gardasil-9) is one of 19 biologic programs targeting Immune Response. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Immune Response
#DrugCompanyPhaseTrials
1Influenza Vaccine
NovartisPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
Xylocaine
MMEDRx USA, Inc.
Phase 2
Flumist
AstraZenecaPhase 3
Decadron
AAspen Global Incorporated
Phase 2
INMAZEB
RegeneronPhase 2
Rmenb+omv
NovartisPhase 3
HPV nonavalent vaccine (Gardasil-9)
CCanadian Immunization Research Network
Phase 3
Immunonutrition
SSt. Antonius Hospital
Phase 3
Ervebo
AANRS, Emerging Infectious Diseases
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details